Identification and optimization of a novel series of selective PIP5K inhibitors.

Amides / chemistry Animals Caco-2 Cells Dose-Response Relationship, Drug Enzyme Inhibitors / chemistry Humans Microsomes, Liver / chemistry Molecular Structure Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors Rats Structure-Activity Relationship
In vitro tools Lipid kinase inhibitors Oncology PI3K PIP5K

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 22 09 2021
revised: 02 12 2021
accepted: 03 12 2021
pubmed: 19 12 2021
medline: 24 2 2022
entrez: 18 12 2021
Statut: ppublish

Résumé

Phosphatidyl inositol (4,5)-bisphosphate (PI(4,5)P

Identifiants

DOI: 10.1016/j.bmc.2021.116557 PMID: 34922306
pubmed: 34922306
pii: S0968-0896(21)00565-4
doi: 10.1016/j.bmc.2021.116557
pii:
doi:

Substances chimiques

Amides 0
Enzyme Inhibitors 0
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
1-phosphatidylinositol-4-phosphate 5-kinase EC 2.7.1.68

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116557

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

David M Andrews (DM)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Sharon Cartic (S)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Sabina Cosulich (S)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Nullin Divecha (N)

Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, Life Sciences Building 85, University of Southampton, Highfield Campus, Southampton, SO17 1BJ, UK.

Paul Faulder (P)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Vikki Flemington (V)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Oliver Kern (O)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Jason G Kettle (JG)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Ellen MacDonald (E)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Jennifer McKelvie (J)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Kurt G Pike (KG)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Bryan Roberts (B)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Rachel Rowlinson (R)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

James M Smith (JM)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK. Electronic address: james.smith3@astrazeneca.com.

Martin Stockley (M)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Martin E Swarbrick (ME)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Iris Treinies (I)

Cancer Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

Michael J Waring (MJ)

Medicinal Chemistry, Oncology R&D, Research and Early Development, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Amides › Identification and optimization of a novel...
questionsmedicales.fr › Eucaryotes › Animaux › Identification and optimization of a novel...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Caco-2 › Identification and optimization of a novel...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Identification and optimization of a novel...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Identification and optimization of a novel...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identification and optimization of a novel...
questionsmedicales.fr › Cellules › Structures cellulaires › Fractions subcellulaires › Microsomes › Microsomes du foie › Identification and optimization of a novel...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Identification and optimization of a novel...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Phosphotransferases (Alcohol Group Acceptor) › Identification and optimization of a novel...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Identification and optimization of a novel...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Identification and optimization of a novel...